Cipla Q1 results: Profit up 10%, margin at 25.6%

What investors are tracking ahead of July 23, 2026

Cipla has a board meeting scheduled for July 23, 2026 to consider the audited financial results and to recommend a dividend for FY2026. The date also aligns with the market’s tracking of the company’s earnings calendar, with the upcoming results tagged as Q1 FY2026-27. The stock’s key reference points on the day include a market capitalisation of ₹114,609.01 crore and a closing market price (CMP) of ₹1,418.7. For context, the immediately previous quarter referenced in the data set is Q4 FY26, when consolidated revenue stood at ₹6,541 crore and profit after tax (PAT) was ₹555 crore. Q4 FY26 EBITDA margin was 15.2%, which is notably lower than the June-quarter margin reported in the Q1 release discussed below.

Q1 performance snapshot: revenue, profit, and operating margin

For the June quarter (Q1 FY26), Cipla reported revenue from operations of ₹6,957 crore, up about 3.9% year-on-year from ₹6,694 crore. Consolidated net profit for the quarter rose 10.2% year-on-year to ₹1,297.62 crore from ₹1,177.64 crore. EBITDA for the quarter was reported at ₹1,778 crore versus ₹1,716 crore a year earlier, while the EBITDA margin stood at 25.6%. Profit before tax (PBT) was reported at ₹1,770 crore for the quarter. In the same dataset, the company’s diluted normalised EPS is shown at 16.06 for the June period.

QoQ detail from the quarterly table

The quarterly comparison table (QoQ basis) shows total revenue of ₹6,957.47 crore for the June period versus ₹6,541.20 crore in the March period. Operating income is shown at ₹1,525.42 crore for June compared with ₹572.03 crore for March. Net income in the table is ₹1,297.62 crore for June versus ₹554.64 crore for March. Operating expense is listed at ₹5,432.05 crore for June, marginally lower than ₹5,969.17 crore in March. Depreciation and amortisation is shown at ₹252.72 crore for June compared with ₹382.92 crore in March.

India, North America, and other markets: what drove the quarter

Cipla said its One-India business grew 6% year-on-year in the quarter and crossed ₹3,000 crore for the first time in the opening quarter of any financial year. The company also stated that One-India now accounts for 44% of its global revenue. Branded and generic therapies were cited as drivers, along with the launch of seven new products. In North America, Cipla reported revenue of $126 million, supported by sales of recently launched products such as Nano Paclitaxel vials and Nilotinib capsules. The Africa business recorded an 11% increase in revenue in US dollar terms, while Europe and emerging markets grew 8% year-on-year, according to a BSE filing referenced in the text.

Margins, costs, and R&D spending

Cipla reported a gross margin after material costs of 68.8%, an increase of 156 basis points year-on-year, attributing the change to product mix and portfolio management. It also disclosed R&D investment of ₹432 crore, or 6.2% of sales, focused on product filings and development. Separately, total expenses were reported as rising 3.9% year-on-year to ₹5,446.10 crore, though they fell 1.3% sequentially from ₹5,514.85 crore. The company also stated that the effective tax rate (ETR) stood at 27%, unchanged year-on-year. PAT for the quarter was described as ₹1,298 crore, representing 18.7% of sales.

Balance sheet and cash position

Cipla said total debt stood at ₹459 crore as on June 30 (as described in the company commentary), and it also disclosed a net cash equivalent balance of ₹10,379 crore. In a separate disclosure in the same text set, the company noted debt reduced to ₹459 crore by June 2025 from ₹547 crore in June 2024. The combination of lower debt and sizeable cash balance is positioned by management as a reflection of operating efficiency and free cash flow generation. These figures are often tracked closely by investors alongside profit growth, particularly for large pharmaceutical companies managing R&D pipelines and global launches.

FY26 context: full-year revenue and profitability

For FY26, Cipla reported consolidated revenue of ₹28,163 crore. Within that, Q4 revenue was ₹6,541 crore. FY26 EBITDA margin was reported at 21%, while Q4 EBITDA margin was reported at 15.2%. PAT for FY26 was stated at ₹3,879 crore, implying a PAT margin of 13.8%, while Q4 PAT was ₹555 crore. A separate line item in the provided text shows net profit for FY26 at ₹3,861.74 crore and total comprehensive income at ₹4,549.48 crore.

Quick reference table: dates, price, and key quarterly figures

Key Q1 FY26 numbers in one view

Market impact and why the July 23 meeting matters

Following the Q1 performance update, the stock was described as gaining 3% in the referenced report. The July 23, 2026 board meeting matters for two reasons in the current context: it is scheduled to consider audited financial results, and it will also evaluate a dividend recommendation for FY2026. For investors, dividend-related decisions can be as material as quarterly earnings, especially when combined with balance-sheet disclosures like net cash and debt. Separately, the company reiterated an EBITDA margin guidance range of 23.5% to 24.5% for the full year, consistent with what it had communicated previously.

Conclusion

Cipla’s disclosed June-quarter performance shows revenue growth to ₹6,957 crore and a 10% year-on-year rise in consolidated profit to about ₹1,298 crore, alongside a 25.6% EBITDA margin. The company also highlighted an India business milestone of crossing ₹3,000 crore in Q1 and reported $126 million revenue in North America. For FY26, it reported consolidated revenue of ₹28,163 crore and PAT of ₹3,879 crore, while also disclosing net profit and total comprehensive income figures. The next near-term milestone is the July 23, 2026 board meeting, where audited results and a dividend recommendation for FY2026 are on the agenda.